Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Insulin Delivery for Memory Loss

Start: July 16, 2020
End: October 2025
Enrollment: 30

What Is This Study About?

Growing evidence suggests that insulin affects normal memory processes and that abnormal insulin levels may contribute to cognitive and brain changes associated with Alzheimer's disease. The Study of Nasal Insulin to Fight Forgetfulness (SNIFF) will test devices that deliver insulin through the nose, and the effects of insulin on memory and insulin levels in the blood and cerebrospinal fluid. Participants will be randomized to receive either 20 or 40 units of insulin, delivered through the nose, over two study visits. Researchers will measure changes in memory, biomarkers for Alzheimer's disease, and insulin levels in the blood and cerebrospinal fluid.

Do I Qualify To Participate in This Study?

Minimum Age: 55 Years

Maximum Age: 85 Years

Must have:

  • Fluent in English
  • Cognitively normal or diagnosis of amnestic mild cognitive impairment
  • Medical conditions stable for three months prior to screening visit
  • Medications stable for four weeks prior to the screening and study visits
  • Laboratory test values within normal limits or, if abnormal, must be clinically insignificant

Must NOT have:

  • Diagnosis of dementia
  • History of stroke
  • Current evidence or history in past two years of epilepsy, head injury with loss of consciousness, any major psychiatric disorder including psychosis, major depression, or bipolar disorder
  • Diagnosis of diabetes (type 1 or type 2)
  • Current or past regular use of insulin or any other medications to treat diabetes within two months of screening visit
  • History of seizure within past five years
  • Pregnancy or possible pregnancy
  • Use of anticoagulants, such as warfarin (Coumadin) or dabigatran (Pradaxa)
  • Residence in a skilled nursing facility at screening
  • Use of any other study drug or device within two months of screening visit
  • Regular use of alcohol, narcotics, anticonvulsants, or anti-parkinsonian medications

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.


Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Wake Forest University Health Sciences

Source: ID: NCT04199767

An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health